Claims:

1. A kit comprising a plurality of sets, each set being of 3 to 10 separate units dosage form, to be administered concomitantly, said 3 to 10 separate units dosage form comprising a therapeutically active agent and an absorption enhancer, wherein said 3 to 10 separate units dosage form together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein each of said sets is packaged individually in said kit, and wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4- chlorobenzoyl)aminobutanoic acid) and salts thereof, said therapeutically active agent is PTH(1-34), and at least 50% by weight of said 3 to 10 separate units dosage form consists of said absorption enhancer.

2. The kit according to claim 1, wherein said 3 to 10 separate units dosage form is for increasing a Cmax and/or a bioavailability of said PTH(1-34), as compared with a corresponding single unit dosage form having the same total composition as said 3 to 10 separate units dosage form.

3. The kit according to any one of claims 1 to 2, wherein said 3 to 10 separate units dosage form is for reducing a variability of Cmax and/or AUC of plasma concentrations of said PTH(1-34), as compared with a corresponding single unit dosage form having the same total composition as said 3 to 10 separate units dosage form.

4. Use of 3 to 10 separate units dosage form comprising PTH(1-34), and an absorption enhancer selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4- chlorobenzoyl)aminobutanoic acid) and salts thereof, in the manufacture of a medicament for the treatment of a condition treatable by said PTH(1-34), wherein said medicament being for concomitant oral administration of the 3 to 10 separate units dosage form, wherein said 3 to 10 separate units dosage form together comprise

a therapeutically effective amount of said PTH(1-34) and an effective amount of said absorption enhancer.

5. The use according to claim 4, wherein said medicament is for increasing a Cmax and/or a bioavailability of said PTH(1-34), as compared with a corresponding treatment by oral administration of a single unit dosage form having the same total composition as said 3 to 10 separate units dosage form.

6. The use according to any one of claims 4 to 5, wherein said medicament is for reducing a variability of Cmax and/or AUC of plasma concentrations of said PTH(1-34), as compared with a corresponding treatment by oral administration of a single unit dosage form having the same total composition as said 3 to 10 separate units dosage form.